Skip to content

Neurochemical Research

ISSN 0364-3190

2 papers in the library · 2 citations · publishing 1977-2026

Papers

Regional localization of [14C]mescaline in rabbit brain after intraventricular administration

Neurochemical Research June 1, 1977 Nandkumar S. Shah, O. D. Dulati, D. A. Powell et al. 2 citations

After injecting radioactive mescaline into the lateral ventricle of anesthetized albino rabbits, the compound rapidly distributed across 12 brain regions, peaking within 15 minutes. Highest mescaline concentrations (23-57 nmol/g) appeared in the spinal cord, superior colliculus, pons, hypothalamus, caudate, medulla oblongata, and inferior colliculus; the cerebrum and hippocampus contained less than 10 nmol/g. Levels of both mescaline and its deaminated metabolite TMPA fell considerably by 180 minutes. Pretreatment with chlorpromazine lowered mescaline in limbic system areas (hippocampus, caudate, thalamus, cerebrum) and raised it elsewhere; iproniazid uniformly reduced TMPA and increased mescaline. The chlorpromazine effect on limbic regions may relate to its antihallucinogenic action in humans.

DOI: 10.1007/bf00969357 Mescaline Cerebrum Medulla oblongata Pons +9

Esketamine Suppresses Astrocyte-Driven Neuroinflammation in Traumatic Brain Injury via the METTL5/c-Myc/PD-L1

Neurochemical Research March 13, 2026 Lan Luo, Miao Yu, Xiaodong Li et al.

Esketamine given to mice after traumatic brain injury (TBI) improved neurological outcomes, reduced neuronal death, and lessened neuroinflammation. The drug suppressed astrocyte activation, inhibited pro-inflammatory A1 astrocyte differentiation, and promoted protective A2 astrocyte formation. These effects occurred through inhibition of the METTL5/c-Myc/PD-L1 signaling pathway. The findings suggest esketamine has significant anti-inflammatory and neuroprotective properties that could be relevant for treating TBI.

DOI: 10.1007/s11064-026-04724-8 Full text Neuroinflammation Astrocyte Traumatic brain injury Neuroprotection +9